Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

IDEAL:  Incremental Decrease in End Points Through Aggressive Lipid Lowering

Principal contacts

Terje Pedersen (University of Oslo)

CTD@Pfizer.com

data custodian

Pfizer Inc.

funding

Pfizer Inc.

key publications